Advancing Retinal Degeneration Treatment through Therapeutic TREM2 Modulation
Background
Retinal degenerative diseases such as retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are characterized by progressive loss of vision leading to blindness. These conditions affect millions globally, with RP alone impacting approximately 1 in 4,000 people worldwide. Current treatment options for retinitis pigmentosa include vitamins and supplements, gene therapy, retinal implants, and vision rehabilitation; however, despite these advancements, there remains significant room for improvement in effectively managing the disease. Activated microglia migrate to the photoreceptor outer nuclear layer in RP patients, contributing to cell death. TREM2, a receptor on myeloid cells, regulates microglia functions critical to maintaining central nervous system stability. Mutations in the TREM2 gene are linked to increased risk of neurodegenerative diseases, although its role in retinal degeneration is not fully understood.
Technology Overview
This innovative therapeutic approach enhances the expression and activity of TREM2 to treat retinal degeneration. By utilizing various agents like peptides, nucleic acids, antibodies, or CRISPR, the technology modulates TREM2 levels, offering a protective effect against retinal degeneration. Proof-of-concept studies in genetic mouse models demonstrate that increased TREM2 expression mitigates photoreceptor degeneration and reduces microglial infiltration, which exacerbates rod degeneration. Furthermore, this approach inhibits inflammatory pathways, offering substantial benefits over current treatments.
Applications
- Treatment of retinitis pigmentosa
- Treatment of age-related macular degeneration
- Potential application in other retinal degenerative conditions like Leber congenital amaurosis and Usher syndrome
Advantages
- Direct modulation of microglial activity and reduction of inflammation
- Promotes photoreceptor survival and stability
- Potential to slow or prevent progression of retinal degeneration
- Innovative delivery methods enhance therapeutic efficacy
